A I-Q Alfonso

Suggest Changes
Learn More
INTRODUCTION Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous entity, showing a highly variable outcome. In patients with DLBCL relapsed/refractory to first-line treatment with rituximab the(More)
a Facultad de Medicina, Universidad de Navarra, Pamplona, Navarra, Spain b Servicio de Hematología, Clínica Universidad de Navarra, Pamplona, Navarra, Spain c Departamento de Anestesiología, Clínica(More)